An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
Sponsor: Genentech, Inc.